



**ERITREA - HEALTH SYSTEM STRENGTHENING (HSS) SUPPORT**  
**This Decision Letter sets out the Programme Terms of a Programme**

<b>1. Country:</b> Eritrea								
<b>2. Grant number:</b> 0814-ERI-10a-Y								
<b>3. Date of Decision Letter :</b> 21 October 2013								
<b>4. Date of the Partnership Framework Agreement:</b> 16 April 2013								
<b>5. Programme Title:</b> Health Systems Strengthening (HSS)								
<p><b>6. HSS terms:</b></p> <p>The ultimate aim of HSS support is to ensure increased and sustained immunisation coverage through addressing health systems barriers in Country, as specified in:</p> <ul style="list-style-type: none"> <li>• The relevant GAVI HSS/HSFP guidelines – please contact your CRO at <a href="mailto:cwhetham@gavialliance.org">cwhetham@gavialliance.org</a> for the guidelines.</li> <li>• The relevant GAVI HSS/HSFP application form - please contact your CRO at <a href="mailto:cwhetham@gavialliance.org">cwhetham@gavialliance.org</a> for the form.</li> <li>• Country’s approved grant proposal and any responses to the HSS IRC’s request for clarifications.</li> </ul> <p>Any disbursements under GAVI’s HSS cash support will only be made if the following requirements are satisfied:</p> <ul style="list-style-type: none"> <li>• GAVI funding being available;</li> <li>• Submission of satisfactory Annual Progress Reports (APRs) by the Country;</li> <li>• Approval of the recommendation by an Independent Review Committee (IRC) for continued support by GAVI after the second year;</li> <li>• Compliance with any TAP requirements pursuant to the TAP Policy and under any Aide Memoire concluded between GAVI and the Country;</li> <li>• Compliance with GAVI’s standard terms and conditions (attached in Appendix [D] or as set out in the PFA); and</li> <li>• Compliance with the then-current GAVI requirements relating to financial statements and external audits, including the requirements set out for annual external audit applicable to all GAVI cash grants as set out in GAVI’s grant terms and conditions.</li> </ul>								
<b>7. Programme Duration<sup>1</sup>:</b> 2008-2014								
<p><b>8. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement, if applicable):</b></p> <table border="1"> <thead> <tr> <th></th> <th>2008-2013</th> <th>2014</th> <th>Total<sup>2</sup></th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td>US\$2,062,750</td> <td>US\$715,250</td> <td>US\$2,778,000</td> </tr> </tbody> </table>		2008-2013	2014	Total <sup>2</sup>	Programme Budget (US\$)	US\$2,062,750	US\$715,250	US\$2,778,000
	2008-2013	2014	Total <sup>2</sup>					
Programme Budget (US\$)	US\$2,062,750	US\$715,250	US\$2,778,000					
<p><b>9. Indicative Annual Amounts (indicative) (subject to the terms of the Partnership Framework Agreement):</b></p> <p>The following disbursements are subject to the conditions set out in sections 6, 10, 11 and 12:</p> <table border="1"> <thead> <tr> <th>Programme Year</th> <th>2008-2013</th> <th>2014</th> <th>Total<sup>3</sup></th> </tr> </thead> <tbody> <tr> <td>Annual Amount (SUS)</td> <td>US\$2,062,750</td> <td>US\$715,250</td> <td>US\$2,778,000</td> </tr> </tbody> </table>	Programme Year	2008-2013	2014	Total <sup>3</sup>	Annual Amount (SUS)	US\$2,062,750	US\$715,250	US\$2,778,000
Programme Year	2008-2013	2014	Total <sup>3</sup>					
Annual Amount (SUS)	US\$2,062,750	US\$715,250	US\$2,778,000					

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the amount approved by GAVI.

**10. Financial Clarifications:** The Country shall provide the following clarifications to GAVI<sup>4</sup>: N/A

**11. Documents/information to be delivered prior to HSS cash disbursement (Financial clarifications):** N/A

**12. Documents to be delivered for future HSS cash disbursements:**

The Country shall deliver the following documents by the specified due dates as part of the conditions for approval and disbursements of the future Annual Amounts.

Reports, documents and other deliverables	Due dates
Annual Progress Reports (APRs). The APRs shall provide detail on the progress against milestones and targets against baseline data for indicators identified in the proposal, as well as the PBF indicators as listed in section 6 above. The APRs should also include a financial report on the use of GAVI support for HSS (which could include a joint pooled funding arrangement report, if appropriate).	15 May 2014 or as negotiated with Secretariat
Interim unaudited financial reports. Unless stated otherwise in the existing Aide Memoire between GAVI and the Country, the Country shall deliver interim unaudited financial reports on the HSS cash support no later than 45 days after the end of each 6-month reporting period (15 February for the period covering 1 July – 31 December and 15 August for the period covering 1 January – 30 June). Failure to submit timely reports may affect future funding.	15 February and 15 August
In order to receive a disbursement for the second approved year of the HSS grant (2014), Country shall provide GAVI with a request for disbursement, which shall include the most recent interim unaudited financial report.	As necessary

**13. Other conditions: The following terms and conditions shall apply to HSS support.**

Cash disbursed under HSS support may not be used to meet GAVI's requirements to co-finance vaccine purchases.

In case the Country wishes to alter the disbursement schedule over the course of the HSFP programme, this must be highlighted and justified in the APR and will be subject to GAVI approval. It is essential that Country's Health Sector Coordination Committee (or its equivalent) be involved with this process both in its technical process function and its support during implementation and monitoring of the HSFP programme proposal. Utilisation of GAVI support stated in this letter will be subject to performance monitoring.

Signed by,

**On behalf of the GAVI Alliance**

Hind Khatib-Othman

Managing Director, Country Programmes

21 October 2013

<sup>4</sup> Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements

**ERITREA – PENTAVALENT VACCINE SUPPORT**  
**This Decision Letter sets out the Programme Terms of a Programme**

<b>1. Country:</b> Eritrea				
<b>2. Grant Number:</b> 0815-ERI-04a-X				
<b>3. Date of Decision Letter :</b> 21 October 2013				
<b>4. Date of the Partnership Framework Agreement:</b> 16 April 2013				
<b>5. Programme Title:</b> New Vaccine Support				
<b>6. Vaccine type:</b> Pentavalent				
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose(s) per vial, LIQUID				
<b>8. Programme Duration<sup>5</sup>:</b> 2008 - 2015				
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>				
	2008-2013	2014	2015	Total <sup>6</sup>
Programme Budget (US\$)	US\$5,220,473 <sup>7</sup>	US\$577,000	US\$650,500	US\$6,447,973
<b>10. Vaccine Introduction Grant:</b> N/A				
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>8</sup></b>				
Type of supplies to be purchased with GAVI funds in each year	2008-2013	2014		
Number of Pentavalent vaccines doses		272,600		
Number of AD syringes		314,900		
Number of safety boxes		3,500		
Annual Amounts (US\$)	US\$5,220,473 <sup>9</sup>	US\$577,000		
<b>12. Procurement agency:</b> UNICEF				
The Country shall release its Co-Financing Payments each year to UNICEF				
<b>13. Self-procurement:</b> N/A				

<sup>5</sup> This is the entire duration of the programme.

<sup>6</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>7</sup> This is the consolidated amount for all previous years.

<sup>8</sup> This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

<sup>9</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations: Reference code: 0815-ERI-04a-X-C** - According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2014	2015
Number of vaccine doses	29,500	33,500
Value of vaccine doses (US\$)	US\$57,452	
Total Co-Financing Payments (US\$) (including freight)	US\$60,500	US\$68,500

**15. Operational support for campaigns:** Not applicable

	2014	2015
Grant amount (US\$)		

**16. Additional documents to be delivered for future disbursements:**

Reports, documents and other deliverables	Due dates
Annual Progress Report	15 May 2014

**17. Financial Clarifications:** N/A

**18. Other conditions:** N/A

Signed by,

**On behalf of the GAVI Alliance**

Hind Khatib-Othman

Managing Director, Country Programmes

21 October 2013

## ERITREA – MEASLES SECOND DOSE VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme

<b>1. Country:</b> Eritrea					
<b>2. Grant Number:</b> 1216-ERI-09a-X					
<b>3. Date of Decision Letter :</b> 21 October 2013					
<b>4. Date of the Partnership Framework Agreement:</b> 16 April 2014					
<b>5. Programme Title:</b> New Vaccine Support					
<b>6. Vaccine type:</b> Measles Second Dose					
<b>7. Requested product presentation and formulation of vaccine:</b> Measles, 10 dose(s) per vial, LYOPHILISED					
<b>8. Programme Duration<sup>10</sup>:</b> 2012 - 2016					
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>					
	2012-2013	2014	2015	2016	Total <sup>11</sup>
Programme Budget (US\$)	US\$88,477 <sup>12</sup>	US\$55,000	US\$59,000	US\$60,000	US\$262,477
<b>10. Vaccine Introduction Grant:</b> N/A					
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>13</sup></b>					
Type of supplies to be purchased with GAVI funds in each year	2012-2013	2014			
Number of Measles vaccines doses		150,700			
Number of AD syringes		99,300			
Number of re-constitution syringes		16,600			
Number of safety boxes		1,300			
Annual Amounts (US\$)	US\$88,477 <sup>14</sup>	US\$55,000			
<b>12. Procurement agency:</b> UNICEF					
<b>13. Self-procurement:</b> N/A					
<b>14. Co-financing obligations:</b> N/A					

<sup>10</sup> This is the entire duration of the programme.

<sup>11</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>12</sup> This is the consolidated amount for all previous years.

<sup>13</sup> This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

<sup>14</sup> This is the consolidated amount for all previously approved years.

**15. Operational support for campaigns: N/A**

	2014	2015
Grant amount (US\$)		

**16. Additional documents to be delivered for future disbursements:**

Reports, documents and other deliverables	Due dates
Annual Progress Report	15 May 2014

**17. Financial Clarifications: N/A**

**18. Other conditions: N/A**

Signed by,



**On behalf of the GAVI Alliance**

Hind Khatib-Othman

Managing Director, Country Programmes

21 October 2013

**ERITREA – ROTAVIRUS VACCINE SUPPORT**  
**This Decision Letter sets out the Programme Terms of a Programme**

<b>1. Country:</b> Eritrea				
<b>2. Grant Number:</b> 1316-ERI-13b-X / 13-ERI-08b-Y				
<b>3. Date of Decision Letter :</b> 21 October 2013				
<b>4. Date of the Partnership Framework Agreement:</b> 16 April 2013				
<b>5. Programme Title:</b> New Vaccine Support				
<b>6. Vaccine type:</b> Rotavirus				
<b>7. Requested product presentation and formulation of vaccine:</b> Rota, 2 dose(s)				
<b>8. Programme Duration<sup>15</sup>:</b> 2014 - 2016				
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>				
	2014	2015	2016	Total <sup>16</sup>
Programme Budget (US\$)	US\$293,000	US\$486,500	US\$501,000	US\$1,280,500
<b>10. Vaccine Introduction Grant:</b> US\$100,000 payable in 2014.				
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>17</sup></b>				
Type of supplies to be purchased with GAVI funds in each year			2014	
Number of Rotavirus vaccines doses			116,400	
Annual Amounts (US\$)			US\$293,000	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.				
<b>13. Self-procurement:</b> N/A				

<sup>15</sup> This is the entire duration of the programme.

<sup>16</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>17</sup> This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

**14. Co-financing obligations: Reference code:** 1316-ERI-13b-X-C - According to the Co-Financing Policy, the Country falls within the Low Income group. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2014	2015	2016
Number of vaccine doses	10,100	16,700	17,200
Value of vaccine doses (US\$)	US\$23,986		
Total Co-Financing Payments (US\$) (including freight)	US\$25,500	US\$42,000	US\$43,500

**15. Operational support for campaigns:** N/A

	2014	2015
Grant amount (US\$)		

**16. Additional documents to be delivered for future disbursements:**

Reports, documents and other deliverables	Due dates
Annual Progress Report	15 May 2014

**17. Clarifications:**

**18. Other conditions:** N/A

Signed by,



**On behalf of the GAVI Alliance**

Hind Khatib-Othman

Managing Director, Country Programmes

21 October 2013